Related Experiment Video
Updated: Jun 22, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Mechanisms underlying methotrexate-induced pulmonary toxicity.
Youn-Jung Kim1, Mee Song, Jae-Chun Ryu
1Korea Institute of Science and Technology, Cellular and Molecular Toxicology Laboratory, Cheongryang, Seoul, Korea.
Expert Opinion on Drug Safety
|June 23, 2009
Summary
Methotrexate (MTX) can cause serious lung toxicity through complex mechanisms. Understanding these pathways, including genotype mutation and p38 MAPK signaling, is key to optimizing MTX therapy.
Area of Science:
- Pharmacology
- Toxicology
- Pulmonary Medicine
Background:
- Methotrexate (MTX) is a vital drug for inflammatory diseases, rheumatoid arthritis, and cancers.
- MTX-induced pulmonary toxicity is an unpredictable and severe adverse effect.
- This toxicity presents as allergic, cytotoxic, or immunologic reactions, posing a significant clinical challenge.
Purpose of the Study:
- To elucidate the complex mechanisms underlying Methotrexate-induced pulmonary toxicity.
- To provide a comprehensive overview of MTX's adverse pulmonary effects.
Main Methods:
- Literature review of studies on MTX-induced pulmonary toxicity.
- Analysis of mechanisms contributing to MTX's adverse pulmonary effects.
Main Results:
- MTX toxicity mechanisms are multifaceted, involving anti-inflammatory and immunosuppressive actions.
- Key mechanisms include genotype mutation, transport inhibition, MTX-polyglutamate formation, and P-glycoprotein interactions.
- The p38 MAPK signaling pathway is significantly implicated in the pulmonary inflammatory response.
Conclusions:
- The diverse mechanisms of MTX toxicity necessitate a thorough understanding for clinical application.
- Identifying these pathways can guide strategies to optimize drug treatment and mitigate pulmonary side effects.
- Further research into MTX-induced pulmonary toxicity mechanisms can improve patient outcomes.
Related Concept Videos
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:26Toxic Reactions: Overview
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
01:17Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
01:25Bioactivation and Tissue Toxicity
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.